Trevena (TRVN) Getting Somewhat Positive Media Coverage, Study Shows
Media stories about Trevena (NASDAQ:TRVN) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Trevena earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.0071895720157 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Trevena, Inc. (TRVN) Earns “Buy” Rating from Oppenheimer Holdings, Inc. (americanbankingnews.com)
- Trevena, Inc. (TRVN) Expected to Announce Earnings of -$0.26 Per Share (americanbankingnews.com)
- Analysts’ Activity: Trevena Inc (TRVN) – ExpertGazette (expertgazette.com)
- Trevena, Inc. (TRVN) Given Buy Rating at HC Wainwright (americanbankingnews.com)
- Trevena, Inc. (TRVN) Announces Quarterly Earnings Results (americanbankingnews.com)
Trevena (NASDAQ TRVN) opened at $1.57 on Tuesday. Trevena has a 1 year low of $1.35 and a 1 year high of $8.00. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.92 and a current ratio of 4.92.
Trevena (NASDAQ:TRVN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.06. During the same quarter last year, the company posted ($0.57) EPS. equities analysts expect that Trevena will post -1.29 EPS for the current year.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Trevena from a “hold” rating to a “sell” rating in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. set a $8.00 target price on shares of Trevena and gave the stock a “buy” rating in a report on Thursday, August 3rd. Cowen and Company reissued a “buy” rating and set a $10.00 target price on shares of Trevena in a report on Friday, August 4th. HC Wainwright reduced their target price on shares of Trevena from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Finally, Barclays PLC lowered shares of Trevena from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $15.00 to $2.50 in a report on Monday, October 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $8.75.
TRADEMARK VIOLATION NOTICE: “Trevena (TRVN) Getting Somewhat Positive Media Coverage, Study Shows” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/trevena-trvn-getting-somewhat-positive-media-coverage-study-shows/1701803.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.